Zhenyuan Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zhenyuan Song has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
Xiaobing Dou
Department of Kinesiology and Nutrition, University of Illinois Chicago, Chicago, IL, USA
15 shared publicationsSongtao Li
Department of Kinesiology and Nutrition, University of Illinois Chicago, Chicago, IL, USA
13 shared publicationsZhigang Wang
Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL; College of Laboratory Medical Science, Harbin Medical University at Daqing, Daqing, Heilongjiang, P.R., China
13 shared publicationsTong Yao
Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL 60612
10 shared publicationsYuwei Jiang
10 shared publicationsQing Song
University of Illinois Chicago
9 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in SSRN Electronic Journal
Pharmacological Restoration of NAD+ Homeostasis Protects Against Cholesterol-Induced Hepatotoxicity by Reactivating the PARP1-AMPK Axis
Background and Aims: Excess hepatic cholesterol contributes to the progression of metabolic liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD), yet the mechanisms by which cholesterol disrupts hepatocellular metabolic homeostasis remain poorly understood. Here, we investigated how cholesterol disrupts hepatic NAD+ homeostasis and whether restoration of this pathway protects against hepatotoxicity.Materials and Methods: Cholesterol-induced hepatotoxicity was investigated using complementary cholesterol-loading models in cultured hepatocytes and mice. Hepatic NAD+ metabolism and its upstream and downstream signaling pathways were examined using pharmacological and genetic approaches.Results: Cholesterol selectively suppressed nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the NAD+ salvage pathway, thereby disrupting intracellular NAD+ homeostasis. Restoration of NAD+ homeostasis by multiple pharmacological approaches attenuated cholesterol-induced hepatocyte injury and restored PARP1-dependent AMPK signaling in vitro and in vivo. Mechanistically, cholesterol suppressed O-GlcNAc transferase (OGT) expression and protein O-GlcNAcylation, resulting in impaired SP1 transcriptional activity, repression of Nampt, disruption of hepatic NAD+ homeostasis, and subsequent inhibition of the PARP1-AMPK adaptive pathway. PARP1 emerged as the principal downstream effector linking impaired NAD+ homeostasis to defective AMPK activation and hepatocyte adaptation during cholesterol stress. Cholesterol-induced hepatotoxicity occurred independently of SIRT1 and mTORC1 signaling, indicating a distinct pathogenic mechanism.Conclusions: These findings identify the OGT-SP1-NAMPT-NAD+-PARP1-AMPK axis as a previously unrecognized adaptive metabolic defense pathway that preserves hepatocyte metabolic resilience during cholesterol overload. These findings establish a mechanistic framework for therapeutic strategies that preserve metabolic adaptation in liver diseases associated with cholesterol overload.
- 23 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPharmacological Restoration of NAD+ Homeostasis Protects Against Cholesterol-Induced Hepatotoxicity by Reactivating the PARP1-AMPK Axis
Background and Aims: Excess hepatic cholesterol contributes to the progression of metabolic liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD), yet the mechanisms by which cholesterol disrupts hepatocellular metabolic homeostasis remain poorly understood. Here, we investigated how cholesterol disrupts hepatic NAD+ homeostasis and whether restoration of this pathway protects against hepatotoxicity.Materials and Methods: Cholesterol-induced hepatotoxicity was investigated using complementary cholesterol-loading models in cultured hepatocytes and mice. Hepatic NAD+ metabolism and its upstream and downstream signaling pathways were examined using pharmacological and genetic approaches.Results: Cholesterol selectively suppressed nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the NAD+ salvage pathway, thereby disrupting intracellular NAD+ homeostasis. Restoration of NAD+ homeostasis by multiple pharmacological approaches attenuated cholesterol-induced hepatocyte injury and restored PARP1-dependent AMPK signaling in vitro and in vivo. Mechanistically, cholesterol suppressed O-GlcNAc transferase (OGT) expression and protein O-GlcNAcylation, resulting in impaired SP1 transcriptional activity, repression of Nampt, disruption of hepatic NAD+ homeostasis, and subsequent inhibition of the PARP1-AMPK adaptive pathway. PARP1 emerged as the principal downstream effector linking impaired NAD+ homeostasis to defective AMPK activation and hepatocyte adaptation during cholesterol stress. Cholesterol-induced hepatotoxicity occurred independently of SIRT1 and mTORC1 signaling, indicating a distinct pathogenic mechanism.Conclusions: These findings identify the OGT-SP1-NAMPT-NAD+-PARP1-AMPK axis as a previously unrecognized adaptive metabolic defense pathway that preserves hepatocyte metabolic resilience during cholesterol overload. These findings establish a mechanistic framework for therapeutic strategies that preserve metabolic adaptation in liver diseases associated with cholesterol overload.
- Open Access
- 14 July 2026
- Published by Elsevier in SSRN Electronic Journal
Chicago, IL, July 5, 2026 To: Biochemical Pharmacology Editorial Office Pharmacological Restoration of NAD+ Homeostasis Protects against Cholesterol-Induced Hepatotoxicity by Reactivating the PARP1-AMPK Axis
Excess hepatic cholesterol contributes to the progression of metabolic liver diseases, including both metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD), yet the mechanisms by which cholesterol disrupts hepatocellular metabolic homeostasis and promotes liver injury remain poorly understood. Here, we investigated whether disruption of hepatic NAD⁺ homeostasis contributes to cholesterol-induced hepatotoxicity and evaluated the underlying molecular mechanisms and therapeutic potential of restoring NAD+ metabolism. Using cholesterol-loading models in cultured hepatocytes and mice, we found that cholesterol markedly disrupted hepatic NAD+ homeostasis by suppressing nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway. Pharmacological restoration of NAD+ homeostasis with nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), nicotinamide N-methyltransferase (NNMT) inhibitors, or preservation of protein PARylation through PARG inhibition effectively attenuated cholesterol-induced hepatocyte injury, restored PARP1 activity, and reactivated AMPK signaling both in vitro and in vivo. Mechanistically, cholesterol suppressed O-GlcNAc transferase (OGT) expression and protein O-GlcNAcylation, leading to SP1 inactivation, transcriptional repression of Nampt, disruption of NAD+ homeostasis, and subsequent inhibition of the PARP1-AMPK signaling axis. We further identified PARP1 as a positive regulator of AMPK via PARPylation, thereby linking impaired NAD+ homeostasis to defective adaptation to metabolic stress. In contrast to saturated fatty acid-induced lipotoxicity, cholesterol-induced hepatotoxicity occurred independently of SIRT1 and mTORC1 signaling, indicating a distinct pathogenic mechanism. Collectively, these findings identify the OGT-SP1-NAMPT-NAD+-PARP1-AMPK axis as a previously unrecognized mechanism underlying cholesterol-induced hepatotoxicity and demonstrate that pharmacological restoration of NAD+ homeostasis represents a promising therapeutic strategy for cholesterol-associated liver diseases.
- 14 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessChicago, IL, July 5, 2026 To: Biochemical Pharmacology Editorial Office Pharmacological Restoration of NAD+ Homeostasis Protects against Cholesterol-Induced Hepatotoxicity by Reactivating the PARP1-AMPK Axis
Excess hepatic cholesterol contributes to the progression of metabolic liver diseases, including both metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD), yet the mechanisms by which cholesterol disrupts hepatocellular metabolic homeostasis and promotes liver injury remain poorly understood. Here, we investigated whether disruption of hepatic NAD⁺ homeostasis contributes to cholesterol-induced hepatotoxicity and evaluated the underlying molecular mechanisms and therapeutic potential of restoring NAD+ metabolism. Using cholesterol-loading models in cultured hepatocytes and mice, we found that cholesterol markedly disrupted hepatic NAD+ homeostasis by suppressing nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway. Pharmacological restoration of NAD+ homeostasis with nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), nicotinamide N-methyltransferase (NNMT) inhibitors, or preservation of protein PARylation through PARG inhibition effectively attenuated cholesterol-induced hepatocyte injury, restored PARP1 activity, and reactivated AMPK signaling both in vitro and in vivo. Mechanistically, cholesterol suppressed O-GlcNAc transferase (OGT) expression and protein O-GlcNAcylation, leading to SP1 inactivation, transcriptional repression of Nampt, disruption of NAD+ homeostasis, and subsequent inhibition of the PARP1-AMPK signaling axis. We further identified PARP1 as a positive regulator of AMPK via PARPylation, thereby linking impaired NAD+ homeostasis to defective adaptation to metabolic stress. In contrast to saturated fatty acid-induced lipotoxicity, cholesterol-induced hepatotoxicity occurred independently of SIRT1 and mTORC1 signaling, indicating a distinct pathogenic mechanism. Collectively, these findings identify the OGT-SP1-NAMPT-NAD+-PARP1-AMPK axis as a previously unrecognized mechanism underlying cholesterol-induced hepatotoxicity and demonstrate that pharmacological restoration of NAD+ homeostasis represents a promising therapeutic strategy for cholesterol-associated liver diseases.
- Open Access
- 18 May 2026
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 22 (11) , 5615-5633
Cholesterol Overload Drives Hepatic Steatosis by Inhibiting OGT-dependent PPARα O-GlcNAcylation and Transactivation
Although dietary cholesterol is known to exacerbate liver disease progression, whether and how it contributes to hepatic steatosis, the hallmark early pathological feature of both MASLD and ALD, remains poorly understood. Here, we investigated how cholesterol disrupts hepatic triacylglycerol metabolism using both dietary and cellular cholesterol-loading models. Integrated transcriptomic, metabolomic, and biochemical analyses were performed, and causality was examined through genetic and pharmacologic modulation in multiple hepatocyte systems and mice. Our results demonstrate that cholesterol overload induces hepatocellular fat accumulation in a dose-dependent, cell-autonomous manner, primarily by suppressing fatty acid β-oxidation. Mechanistically, we identified PPARα inhibition as a key event underlying this effect. Cholesterol overload suppressed PPARα transactivation, thereby impairing fatty acid β-oxidation and promoting hepatocellular fat accumulation. This inhibition was mechanistically linked to reduced O-GlcNAcylation. Specifically, cholesterol overload downregulated OGT, leading to reduced protein O-GlcNAcylation and consequent PPARα inhibition; similarly, liver-specific OGT knockout mice exhibited suppressed PPARα activity and increased hepatic fat accumulation. RNA-sequencing and co-immunoprecipitation analyses identified PPARα as an O-GlcNAc-modified protein, and loss of this modification impaired its transactivity. Functionally, restoration of O-GlcNAcylation via genetic OGA knockdown or pharmacological activation of PPARα with WY14643 alleviated cholesterol-induced hepatic steatosis in mice without altering hepatic cholesterol levels. Lastly, we identified SREBP2 as the upstream transcriptional regulator linking cholesterol overload to OGT suppression. In conclusion, our findings in this study uncover a previously unrecognized cholesterol-OGT-PPARα axis that suppresses hepatic fatty acid β-oxidation and drives steatosis. Targeting O-GlcNAc cycling or activating PPARα represents a promising therapeutic strategy for MASLD.
- 18 May 2026
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 22 (11) , 5615-5633
Open AccessCholesterol Overload Drives Hepatic Steatosis by Inhibiting OGT-dependent PPARα O-GlcNAcylation and Transactivation
Although dietary cholesterol is known to exacerbate liver disease progression, whether and how it contributes to hepatic steatosis, the hallmark early pathological feature of both MASLD and ALD, remains poorly understood. Here, we investigated how cholesterol disrupts hepatic triacylglycerol metabolism using both dietary and cellular cholesterol-loading models. Integrated transcriptomic, metabolomic, and biochemical analyses were performed, and causality was examined through genetic and pharmacologic modulation in multiple hepatocyte systems and mice. Our results demonstrate that cholesterol overload induces hepatocellular fat accumulation in a dose-dependent, cell-autonomous manner, primarily by suppressing fatty acid β-oxidation. Mechanistically, we identified PPARα inhibition as a key event underlying this effect. Cholesterol overload suppressed PPARα transactivation, thereby impairing fatty acid β-oxidation and promoting hepatocellular fat accumulation. This inhibition was mechanistically linked to reduced O-GlcNAcylation. Specifically, cholesterol overload downregulated OGT, leading to reduced protein O-GlcNAcylation and consequent PPARα inhibition; similarly, liver-specific OGT knockout mice exhibited suppressed PPARα activity and increased hepatic fat accumulation. RNA-sequencing and co-immunoprecipitation analyses identified PPARα as an O-GlcNAc-modified protein, and loss of this modification impaired its transactivity. Functionally, restoration of O-GlcNAcylation via genetic OGA knockdown or pharmacological activation of PPARα with WY14643 alleviated cholesterol-induced hepatic steatosis in mice without altering hepatic cholesterol levels. Lastly, we identified SREBP2 as the upstream transcriptional regulator linking cholesterol overload to OGT suppression. In conclusion, our findings in this study uncover a previously unrecognized cholesterol-OGT-PPARα axis that suppresses hepatic fatty acid β-oxidation and drives steatosis. Targeting O-GlcNAc cycling or activating PPARα represents a promising therapeutic strategy for MASLD.
- 1 February 2026
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 330 (2) , G170-G188
Low-dose galactose rebalances HBP-mTORC1-SREBP-1c signaling to suppress hepatic lipogenesis and protect against early-stage alcohol-related liver disease
This study demonstrates that low-dose galactose, a dairy-derived monosaccharide, regulates hepatic de novo lipogenesis (DNL) by selectively inhibiting glucose-induced DNL activation. Mechanistically, low-dose galactose suppresses hexosamine biosynthetic pathway (HBP) flux, protein O-GlcNAcylation, and mTORC1 signaling, thereby inhibiting SREBP-1c activation in a Leloir pathway-dependent manner. Notably, galactose supplementation prevented early-stage alcohol-related liver disease by attenuating hepatic HBP-O-GlcNAcylation-SREBP-1c signaling.
- 1 February 2026
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 330 (2) , G170-G188
Low-dose galactose rebalances HBP-mTORC1-SREBP-1c signaling to suppress hepatic lipogenesis and protect against early-stage alcohol-related liver disease
This study demonstrates that low-dose galactose, a dairy-derived monosaccharide, regulates hepatic de novo lipogenesis (DNL) by selectively inhibiting glucose-induced DNL activation. Mechanistically, low-dose galactose suppresses hexosamine biosynthetic pathway (HBP) flux, protein O-GlcNAcylation, and mTORC1 signaling, thereby inhibiting SREBP-1c activation in a Leloir pathway-dependent manner. Notably, galactose supplementation prevented early-stage alcohol-related liver disease by attenuating hepatic HBP-O-GlcNAcylation-SREBP-1c signaling.
- Open Access
- 9 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (2) , eadz1385
ERα activates NAMPT/IL-33 signaling to enhance beige thermogenesis and metabolic fitness
Beige adipocytes are inducible thermogenic fat cells that emerge within white adipose tissue (WAT) in response to thermogenic stimuli and confer metabolic benefits. However, obesity impairs the generation of beige adipocytes, and the underlying mechanisms remain poorly understood. Here, we show that obesity leads to a loss of adipose progenitor cells (APCs) in WAT, accompanied by reduced estrogen (E2) levels and nicotinamide phosphoribosyltransferase (NAMPT) expression. Supplementation with E2 or nicotinamide mononucleotide (NMN), an NAMPT-derived nicotinamide adenine dinucleotide (NAD + ) precursor, restores beige adipogenesis in diet-induced obese mice. Mechanistically, estrogen receptor α (ERα) in APCs is required for beige fat formation by promoting Nampt transcription. We further demonstrate that NAMPT is both necessary and sufficient to drive APC proliferation and differentiation, with interleukin-33 (IL-33) acting downstream to mediate these effects. These findings uncover a critical ERα/NAMPT/IL-33 axis that preserves progenitor function and thermogenic capacity, offering a potential therapeutic strategy to combat obesity-induced beige fat failure and associated metabolic dysfunction.
- 9 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (2) , eadz1385
Open AccessERα activates NAMPT/IL-33 signaling to enhance beige thermogenesis and metabolic fitness
Beige adipocytes are inducible thermogenic fat cells that emerge within white adipose tissue (WAT) in response to thermogenic stimuli and confer metabolic benefits. However, obesity impairs the generation of beige adipocytes, and the underlying mechanisms remain poorly understood. Here, we show that obesity leads to a loss of adipose progenitor cells (APCs) in WAT, accompanied by reduced estrogen (E2) levels and nicotinamide phosphoribosyltransferase (NAMPT) expression. Supplementation with E2 or nicotinamide mononucleotide (NMN), an NAMPT-derived nicotinamide adenine dinucleotide (NAD + ) precursor, restores beige adipogenesis in diet-induced obese mice. Mechanistically, estrogen receptor α (ERα) in APCs is required for beige fat formation by promoting Nampt transcription. We further demonstrate that NAMPT is both necessary and sufficient to drive APC proliferation and differentiation, with interleukin-33 (IL-33) acting downstream to mediate these effects. These findings uncover a critical ERα/NAMPT/IL-33 axis that preserves progenitor function and thermogenic capacity, offering a potential therapeutic strategy to combat obesity-induced beige fat failure and associated metabolic dysfunction.
- Open Access
- 27 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (26) , eadt6195
Hepatic NMNAT1 is required to defend against alcohol-associated fatty liver disease
Nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1), a nicotinamide adenine dinucleotide (NAD + ) synthetase in Preiss-Handler and salvage pathways, governs nuclear NAD + homeostasis. This study investigated the role of NMNAT1 in alcohol-associated liver disease (ALD). Decreased NMNAT1 expression and activity were observed in the liver of patients with alcohol-associated hepatitis and either liver or primary hepatocytes from ALD mice. F-box and WD repeat domain containing 7 (FBXW7)–regulated interferon regulatory factor 1 (IRF1) ubiquitination degradation contributed to the alcohol-inhibited NMNAT1 transcriptional level. Hepatic NMNAT1 knockout aggravated alcohol-induced hepatic NAD + decline and further hepatic steatosis and liver injury. Metabolomics and transcriptomics interaction revealed that the cysteine sulfinic acid decarboxylase (CSAD)–regulated taurine pathway was involved in NMNAT1-disrupted hepatic lipid metabolism in ALD. Hepatic CSAD overexpression or taurine supply attenuated hepatic NMNAT1 knockout–aggravated ALD. Hepatic NMNAT1 loss inhibited NMN-protected ALD. Replenishing hepatic NMNAT1 reversed liver lipid accumulation in ALD mice. These findings identified NMNAT1 as a promising therapeutic target for ALD.
- 27 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (26) , eadt6195
Open AccessHepatic NMNAT1 is required to defend against alcohol-associated fatty liver disease
Nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1), a nicotinamide adenine dinucleotide (NAD + ) synthetase in Preiss-Handler and salvage pathways, governs nuclear NAD + homeostasis. This study investigated the role of NMNAT1 in alcohol-associated liver disease (ALD). Decreased NMNAT1 expression and activity were observed in the liver of patients with alcohol-associated hepatitis and either liver or primary hepatocytes from ALD mice. F-box and WD repeat domain containing 7 (FBXW7)–regulated interferon regulatory factor 1 (IRF1) ubiquitination degradation contributed to the alcohol-inhibited NMNAT1 transcriptional level. Hepatic NMNAT1 knockout aggravated alcohol-induced hepatic NAD + decline and further hepatic steatosis and liver injury. Metabolomics and transcriptomics interaction revealed that the cysteine sulfinic acid decarboxylase (CSAD)–regulated taurine pathway was involved in NMNAT1-disrupted hepatic lipid metabolism in ALD. Hepatic CSAD overexpression or taurine supply attenuated hepatic NMNAT1 knockout–aggravated ALD. Hepatic NMNAT1 loss inhibited NMN-protected ALD. Replenishing hepatic NMNAT1 reversed liver lipid accumulation in ALD mice. These findings identified NMNAT1 as a promising therapeutic target for ALD.
- 1 June 2025
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 328 (6) , G663-G676
Saturated phosphatidic acids induce mTORC1-driven integrated stress response contributing to glucolipotoxicity in hepatocytes
Integrated stress response (ISR) activation contributes to palmitate-induced lipotoxicity in hepatocytes. mTORC1 acts as an upstream kinase essential for palmitate-mediated ISR activation and hepatocyte death. The formation of saturated phosphatidic acid mechanistically regulates hepatic mTORC1 activation induced by palmitate. Glucose-enhanced generation of saturated phosphatidic acid amplifies palmitate-induced hepatotoxicity, contributing to glucolipotoxicity.
- 1 June 2025
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 328 (6) , G663-G676
Saturated phosphatidic acids induce mTORC1-driven integrated stress response contributing to glucolipotoxicity in hepatocytes
Integrated stress response (ISR) activation contributes to palmitate-induced lipotoxicity in hepatocytes. mTORC1 acts as an upstream kinase essential for palmitate-mediated ISR activation and hepatocyte death. The formation of saturated phosphatidic acid mechanistically regulates hepatic mTORC1 activation induced by palmitate. Glucose-enhanced generation of saturated phosphatidic acid amplifies palmitate-induced hepatotoxicity, contributing to glucolipotoxicity.
- 7 May 2025
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
Glucose Metabolism Through the Hexosamine Biosynthetic Pathway Drives Hepatic De Novo Lipogenesis via Promoting N-linked Protein Glycosylation
De novo lipogenesis (DNL) converts excess glucose into lipids, while the hexosamine biosynthetic pathway (HBP), a glycolytic branch, generates UDP-N-acetylglucosamine (UDP-GlcNAc) for protein glycosylation, including O-GlcNAcylation and N-linked glycosylation. Both pathways are active in hepatocytes and integral to glucose metabolism; however, their functional interplay remains unclear. Here, we investigated the role of HBP in hepatic DNL activation using both in vitro and i n vivo models. AML12 hepatocytes were cultured in low- and high-glucose media with or without HBP blockade, both pharmacologically and genetically. For in vivo studies, male C57BL/6J mice were subjected to a fasting-refeeding regimen with or without intraperitoneal administration of azaserine, a competitive inhibitor of glutamine-fructose-6-phosphate transaminase 1 (GFPT1), the rate-limiting enzyme of the HBP. Our results demonstrated that, in AML12 cells, glucose exposure activated both DNL and HBP, leading to triacylglycerol (TAG) accumulation, while HBP inhibition ameliorates DNL and TAG accumulation. In mice, refeeding after a 24-hour fasting induced hepatic DNL, which was abolished by HBP inhibition, indicating its mechanistic involvement in glucose-driven lipogenesis. Mechanistically, we identified ATF4 as a key regulator of GFPT1 upregulation under high-glucose conditions. As expected, both glucose-treated hepatocytes and livers from fasting-refed mice exhibited increased protein glycosylation. Notably, blocking N-linked glycosylation, but not O-GlcNAcylation, abolished glucose-induced DNL activation, indicating that HBP is essential for glucose-induced DNL pathway activation via promoting N-linked glycosylation, independent of O-GlcNAcylation. In conclusion, our findings establish that an intact HBP is required for glucose-induced hepatic DNL activation, primarily through promoting protein N-linked glycosylation.
- 7 May 2025
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
Glucose Metabolism Through the Hexosamine Biosynthetic Pathway Drives Hepatic De Novo Lipogenesis via Promoting N-linked Protein Glycosylation
De novo lipogenesis (DNL) converts excess glucose into lipids, while the hexosamine biosynthetic pathway (HBP), a glycolytic branch, generates UDP-N-acetylglucosamine (UDP-GlcNAc) for protein glycosylation, including O-GlcNAcylation and N-linked glycosylation. Both pathways are active in hepatocytes and integral to glucose metabolism; however, their functional interplay remains unclear. Here, we investigated the role of HBP in hepatic DNL activation using both in vitro and i n vivo models. AML12 hepatocytes were cultured in low- and high-glucose media with or without HBP blockade, both pharmacologically and genetically. For in vivo studies, male C57BL/6J mice were subjected to a fasting-refeeding regimen with or without intraperitoneal administration of azaserine, a competitive inhibitor of glutamine-fructose-6-phosphate transaminase 1 (GFPT1), the rate-limiting enzyme of the HBP. Our results demonstrated that, in AML12 cells, glucose exposure activated both DNL and HBP, leading to triacylglycerol (TAG) accumulation, while HBP inhibition ameliorates DNL and TAG accumulation. In mice, refeeding after a 24-hour fasting induced hepatic DNL, which was abolished by HBP inhibition, indicating its mechanistic involvement in glucose-driven lipogenesis. Mechanistically, we identified ATF4 as a key regulator of GFPT1 upregulation under high-glucose conditions. As expected, both glucose-treated hepatocytes and livers from fasting-refed mice exhibited increased protein glycosylation. Notably, blocking N-linked glycosylation, but not O-GlcNAcylation, abolished glucose-induced DNL activation, indicating that HBP is essential for glucose-induced DNL pathway activation via promoting N-linked glycosylation, independent of O-GlcNAcylation. In conclusion, our findings establish that an intact HBP is required for glucose-induced hepatic DNL activation, primarily through promoting protein N-linked glycosylation.
- 1 March 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 328 (3) , C776-C790
Increasing cellular NAD+ protects hepatocytes against palmitate-induced lipotoxicity by preventing PARP-1 inhibition and the mTORC1-p300 pathway activation
This study explores the mechanisms of palmitate-induced hepatotoxicity, highlighting the role of PARP-1 downregulation in triggering the mTORC1-p300 pathway and resultant hepatocyte cell death. It further reveals that enhancing cellular NAD+ levels through either precursor supplementation or NNMT inhibitors prevents lipotoxicity by restoring PARP-1 activity. Finally, the study identifies that the TLR4-NF-κB activation mediates palmitate-induced PARP-1 suppression and offers potential therapeutic insights for metabolic liver diseases caused by lipotoxicity.
- 1 March 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 328 (3) , C776-C790
Increasing cellular NAD+ protects hepatocytes against palmitate-induced lipotoxicity by preventing PARP-1 inhibition and the mTORC1-p300 pathway activation
This study explores the mechanisms of palmitate-induced hepatotoxicity, highlighting the role of PARP-1 downregulation in triggering the mTORC1-p300 pathway and resultant hepatocyte cell death. It further reveals that enhancing cellular NAD+ levels through either precursor supplementation or NNMT inhibitors prevents lipotoxicity by restoring PARP-1 activity. Finally, the study identifies that the TLR4-NF-κB activation mediates palmitate-induced PARP-1 suppression and offers potential therapeutic insights for metabolic liver diseases caused by lipotoxicity.
- 22 November 2023
- Published by Elsevier in Metabolism
- Vol. 151, 155740
Gut-derived ammonia contributes to alcohol-related fatty liver development via facilitating ethanol metabolism and provoking ATF4-dependent de novo lipogenesis activation
- 22 November 2023
- Published by Elsevier in Metabolism
- Vol. 151, 155740
Gut-derived ammonia contributes to alcohol-related fatty liver development via facilitating ethanol metabolism and provoking ATF4-dependent de novo lipogenesis activation